Personalis, Inc.

NasdaqGM PSNL

Personalis, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2024: USD 143.65 M

Personalis, Inc. Cash and Short-Term Investments is USD 143.65 M for the quarter ending September 30, 2024, a 19.05% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Personalis, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2023 was USD 120.66 M, a -37.40% change year over year.
Personalis, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2022 was USD 192.76 M, a -36.85% change year over year.
Personalis, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2021 was USD 305.23 M, a 48.12% change year over year.
Personalis, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2020 was USD 206.06 M, a 61.90% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqGM: PSNL

Personalis, Inc.

CEO	Mr. Christopher M. Hall
IPO Date	June 20, 2019
Location	United States
Headquarters	1330 O’Brien Drive
Employees	223
Sector	Healthcare
Industries Biotechnology 3D Printing Big Data

Description

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.

Key trends

Past 5 years